Omega: Flagship’s latest venture into the chromatin white space

Omega’s launch deepens Flagship’s investment in chromatin structure-based gene control

Flagship’s latest foray into white space technologies, Omega Therapeutics, is the newest company to tackle gene control by intervening at the 3-D chromatin structure level.

With a platform that homes in on the structural elements surrounding individual or small groups of genes, the company may be able to selectively regulate gene expression across a broad swath of indications.

Founded in 2017 in Flagship Pioneering’s Flagship Labs

Read the full 668 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE